EP Patent

EP0405425A2 — Heteroarylamino- and heteroaryloxypyridinamines and related compounds, a process for their preparation and their use as medicaments

Assigned to Aventis Pharmaceuticals Inc · Expires 1991-01-02 · 35y expired

What this patent protects

There are described compounds of the formula where n is 0 or 1; X is O or NR₂, R₂ being hydrogen, loweralkyl or loweralkylcarbonyl; Z is NO₂ or NHR where R is hydrogen, loweralkyl, arylloweralkyl or loweralkylcarbonyl; and R₁ is wherein R₃ is hydrogen, lowera…

USPTO Abstract

There are described compounds of the formula where n is 0 or 1; X is O or NR₂, R₂ being hydrogen, loweralkyl or loweralkylcarbonyl; Z is NO₂ or NHR where R is hydrogen, loweralkyl, arylloweralkyl or loweralkylcarbonyl; and R₁ is wherein R₃ is hydrogen, loweralkyl or loweralkylcarbonyl; m is 1 or 2; each R₄ is independently hydrogen or loweralkyl; and Y is hydrogen, halogen, loweralkyl, loweralkoxy or trifluoromethyl; which compounds are useful as topical antiinflammatory agents for the treatment of various dermatoses.

Drugs covered by this patent

Patent Metadata

Patent number
EP0405425A2
Jurisdiction
EP
Classification
Expires
1991-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.